Investor Presentaiton

Paradigm shifts are not easy Liquid biopsy... INVESTOR 20 DAY 23 ...cannot detect late- stage cancer in blood." GUARDANT™ ...is too expensive to run at scale. "I ...is unproven and unreliable." "I ...only detects uninformative cancer information in blood." "I ...will only be used for niche applications." " ...cannot achieve high performance for MRD without tissue." "I ...cannot detect Stage I-III cancers with high sensitivity." 9

View entire presentation